Natriuretic Peptide Receptor A as a Target for Prostate Cancer
Author Information
Author(s): Wang Xiaoqin, Raulji Payal, Mohapatra Shyam S, Patel Ronil, Hellermann Gary, Kong Xiaoyuan, Vera Pedro L, Meyer-Siegler Katherine L, Coppola Domenico, Mohapatra Subhra
Primary Institution: University of South Florida
Hypothesis
The study investigates the role of natriuretic peptide receptor A (NPRA) in prostate cancer (PCa) and its potential as a therapeutic target.
Conclusion
NPRA promotes prostate cancer development by regulating macrophage migration inhibitory factor (MIF), making it a potential prognostic marker and therapeutic target.
Supporting Evidence
- NPRA is abundantly expressed in tumorigenic prostate cells but not in non-tumorigenic cells.
- Down-regulation of NPRA induced apoptosis in prostate cancer cells.
- NPRA expression correlated with clinical staging in human prostate cancer samples.
- NPRA deficiency prevented growth of transplanted prostate cancer cells in mice.
Takeaway
This study found that a protein called NPRA helps prostate cancer grow, and blocking it could be a way to treat the disease.
Methodology
The study used western blotting, RT-PCR, immunohistochemistry, and animal models to assess NPRA expression and its effects on prostate cancer.
Limitations
The study primarily focuses on NPRA's role in mouse models and may not fully translate to human prostate cancer.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website